Abstract Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic
phase (CML-CP) is considered a feasible option, especially with the ability of second …

Background First-line imatinib treatment can be successfully discontinued in patients with
chronic myeloid leukaemia after deep molecular response has been sustained for at least 2 …

Background A previous dasatinib discontinuation (DADI) trial showed that 31 (49%) of 63
patients with chronic-phase chronic myeloid leukaemia who were treated with second-line …

Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous
leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients …

Early molecular response is associated with improved probability of deep molecular
response and superior survival in patients with CML-CP. However,~ 1 in 3 patients on first …

This analysis explores the impact of early cytogenetic and molecular responses on the
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase …

Introduction We previously reported an interim analysis of the DADI (dasatinib
discontinuation) trial. The results showed that 48% of patients with chronic myeloid leukemia …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …

We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-
resistant/-intolerant chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients …

Low‐dose dasatinib is safe and effective in patients with chronic myeloid leukemia in
chronic phase (CML‐CP). No randomized trials have compared the outcome with standard …